Novo Nordisk shares dropped due to CagriSema trial results but have long-term upside. Learn why NVO stock is a Strong Buy ...

Trump could either weaken the negotiations in a way that benefits the pharmaceutical industry, or try to achieve even deeper savings to outdo his predecessor.

We recently published a list of Jim Cramer Discusses These 11 Stocks & President Trump’s Sovereign Wealth Fund.

As part of NJBIZ’s latest virtual discussion, business leaders in New Jersey weighed in on what to expect in the first 100 ...

It’s a bigger deal than any deal announced in 2024 ... the dealmaking environment from a regulatory perspective." Novo Nordisk’s global head of business development and M&A, John MacDonald ...

Novo Nordisk's sales and profits were both up around 30% last quarter. Its GLP-1 weight loss drug has been a driving force ...

Novo Nordisk (NVO) stock took a hit this week, after a Super Bowl ad highlighted a growing challenge to the company’s ...

Novo Nordisk faces challenges but its pipeline remains strong. Find out why NVO stock could deliver high double-digit returns ...

In this article, we are going to take a look at where Novo Nordisk A/S (NYSE ... If you are looking for an AI stock that is more promising than NVO but that trades at less than 5 times its ...

In this video, I will go over Novo Nordisk's (NVO-3.62%) and Eli Lilly's recent earnings report. Watch the short video to learn more, consider subscribing, and click the special offer link below.

Novo Nordisk’s annual results are out and they ... The global prevalence of obesity more than doubled between 1990 and 2022 to 16%. The proximate cause of obesity is eating too much food.